Next Article in Journal
11C-Choline PET/CT vs. 99mTc-MIBI/123Iodide Subtraction SPECT/CT for Preoperative Detection of Abnormal Parathyroid Glands in Primary Hyperparathyroidism: A Prospective, Single-Centre Clinical Trial in 60 Patients
Next Article in Special Issue
Detection of CTNNB1 Hotspot Mutations in Cell-Free DNA from the Urine of Hepatocellular Carcinoma Patients
Previous Article in Journal
The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer
Article

Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury

Department of Internal Medicine I, Gastroenterology, Hepatology, Endocrinology, Rheumatology and Infectious Diseases, University Hospital Regensburg, 93053 Regensburg, Germany
*
Author to whom correspondence should be addressed.
Received: 30 October 2020 / Revised: 18 November 2020 / Accepted: 18 November 2020 / Published: 19 November 2020
(This article belongs to the Special Issue Biomarkers in Hepatocellular Carcinoma)
Hepatitis C virus (HCV)-induced inflammation contributes to progressive liver disease. The chemoattractant protein chemerin is associated with systemic inflammation. We hypothesized that chemerin is a biomarker that predicts the severity of liver disease in HCV patients. Furthermore, we investigated whether serum chemerin levels change during the course of HCV treatment using direct-acting antivirals (DAAs). Therefore, we measured serum concentration of chemerin in a cohort of 82 HCV-infected patients undergoing DAA treatment. Serum chemerin was positively associated with leukocyte count and negatively with markers of hepatic function and the model of end-stage liver disease (MELD) score. Low circulating chemerin levels significantly correlated with advanced liver fibrosis and cirrhosis as measured by the fibrosis-4 (FIB-4) score, the aminotransferase/platelet (AST/PLT) ratio index (APRI) score and the non-alcoholic fatty liver disease (NAFLD) score. Chemerin did not correlate with viral load or viral genotype. Treatment with DAAs did not improve MELD score and leukocyte count within the observation period, up to three months after the end of DAA treatment. Accordingly, chemerin levels remained unchanged during the treatment period. We conclude that low circulating chemerin is a noninvasive biomarker for hepatic dysfunction and advanced liver fibrosis and cirrhosis in HCV infection. View Full-Text
Keywords: HCV infection; DAA; body mass index; MELD score; liver fibrosis HCV infection; DAA; body mass index; MELD score; liver fibrosis
Show Figures

Graphical abstract

MDPI and ACS Style

Peschel, G.; Grimm, J.; Gülow, K.; Müller, M.; Buechler, C.; Weigand, K. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury. Diagnostics 2020, 10, 974. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics10110974

AMA Style

Peschel G, Grimm J, Gülow K, Müller M, Buechler C, Weigand K. Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury. Diagnostics. 2020; 10(11):974. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics10110974

Chicago/Turabian Style

Peschel, Georg, Jonathan Grimm, Karsten Gülow, Martina Müller, Christa Buechler, and Kilian Weigand. 2020. "Chemerin Is a Valuable Biomarker in Patients with HCV Infection and Correlates with Liver Injury" Diagnostics 10, no. 11: 974. https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics10110974

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop